Liu Y - Search Results

1

Sustainably released nanoparticle-based rhynchophylline limits pulmonary fibrosis by inhibiting the TEK-PI3K/AKT signaling pathway.

Wang S, Huang Z, Liu Y, Sun H, Zhou Y, Shi J. Wang S, et al. Among authors: liu y. Transl Lung Cancer Res. 2023 Mar 31;12(3):427-445. doi: 10.21037/tlcr-22-675. Epub 2023 Mar 6. Transl Lung Cancer Res. 2023. PMID: 37057119 Free PMC article.

2

Overexpression of MYCN promotes proliferation of non-small cell lung cancer.

Liu K, Wang S, Liu Y, Gu J, Gu S, Xu Z, Zhang R, Wang Z, Ma H, Chen Y, Ji L. Liu K, et al. Among authors: liu y. Tumour Biol. 2016 Sep;37(9):12855-12866. doi: 10.1007/s13277-016-5236-2. Epub 2016 Jul 23. Tumour Biol. 2016. PMID: 27449038

3

miR-335 inhibited cell proliferation of lung cancer cells by target Tra2β.

Liu J, Bian T, Feng J, Qian L, Zhang J, Jiang D, Zhang Q, Li X, Liu Y, Shi J. Liu J, et al. Among authors: liu y. Cancer Sci. 2018 Feb;109(2):289-296. doi: 10.1111/cas.13452. Epub 2017 Dec 15. Cancer Sci. 2018. PMID: 29161765 Free PMC article.

4

CtBP1 interacts with SOX2 to promote the growth, migration and invasion of lung adenocarcinoma.

Liu Y, Bian T, Feng J, Qian L, Li X, Zhang Q, Zhang J, Jiang D, Liu J, Shi J. Liu Y, et al. Among authors: liu j. Oncol Rep. 2019 Jul;42(1):67-78. doi: 10.3892/or.2019.7142. Epub 2019 May 2. Oncol Rep. 2019. Retraction in: Oncol Rep. 2023 Aug;50(2):151. doi: 10.3892/or.2023.8588 PMID: 31059077 Free PMC article. Retracted.

5

High expression of interleukin-enhancer binding factor 3 predicts poor prognosis in patients with lung adenocarcinoma.

Xu Z, Huang H, Li X, Ji C, Liu Y, Liu X, Zhu J, Wang Z, Zhang H, Shi J. Xu Z, et al. Among authors: liu y, liu x. Oncol Lett. 2020 Mar;19(3):2141-2152. doi: 10.3892/ol.2020.11330. Epub 2020 Jan 22. Oncol Lett. 2020. PMID: 32194712 Free PMC article.

6

Correlation between prognostic indicator AHNAK2 and immune infiltrates in lung adenocarcinoma.

Zheng M, Liu J, Bian T, Liu L, Sun H, Zhou H, Zhao C, Yang Z, Shi J, Liu Y. Zheng M, et al. Among authors: liu j, liu y, liu l. Int Immunopharmacol. 2021 Jan;90:107134. doi: 10.1016/j.intimp.2020.107134. Epub 2020 Nov 7. Int Immunopharmacol. 2021. PMID: 33168407

7

Overexpression of TPX2 predicts poor clinical outcome and is associated with immune infiltration in hepatic cell cancer.

Zhu H, Liu J, Feng J, Zhang Q, Bian T, Li X, Sun H, Zhang J, Liu Y. Zhu H, et al. Among authors: liu j, liu y. Medicine (Baltimore). 2020 Dec 4;99(49):e23554. doi: 10.1097/MD.0000000000023554. Medicine (Baltimore). 2020. PMID: 33285774 Free PMC article.

8

Mining database for the expression and clinical significance of STAT family in head and neck squamous cell carcinomas.

Ni H, Sun H, Zheng M, Bian T, Liu J, Li X, Zhang J, Liu Y. Ni H, et al. Among authors: liu j, liu y. Transl Oncol. 2021 Jan;14(1):100976. doi: 10.1016/j.tranon.2020.100976. Epub 2020 Dec 10. Transl Oncol. 2021. PMID: 33395750 Free PMC article.

9

Molecular and Immune Characteristics for Lung Adenocarcinoma Patients With ERLIN2 Overexpression.

Liu Y, Xie P, Jiang D, Liu J, Zhang J, Bian T, Shi J. Liu Y, et al. Among authors: liu j. Front Immunol. 2020 Dec 7;11:568440. doi: 10.3389/fimmu.2020.568440. eCollection 2020. Front Immunol. 2020. PMID: 33424830 Free PMC article.

10

Prognostic biomarker TUBA1C is correlated to immune cell infiltration in the tumor microenvironment of lung adenocarcinoma.

Bian T, Zheng M, Jiang D, Liu J, Sun H, Li X, Liu L, Zhang J, Liu Y. Bian T, et al. Among authors: liu j, liu y, liu l. Cancer Cell Int. 2021 Mar 2;21(1):144. doi: 10.1186/s12935-021-01849-4. Cancer Cell Int. 2021. PMID: 33653340 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

206,137 results

Search Page

Filters